These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 32708663)

  • 1. Differential Effects of MS Therapeutics on B Cells-Implications for Their Use and Failure in AQP4-Positive NMOSD Patients.
    Traub J; Häusser-Kinzel S; Weber MS
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pediatric-onset multiple sclerosis in Brazilian patients: Clinical features, treatment response and comparison to pediatric neuromyelitis optica spectrum disorders.
    Fragomeni MO; Bichuetti DB; Oliveira EML
    Mult Scler Relat Disord; 2018 Oct; 25():138-142. PubMed ID: 30075406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting B Cells to Modify MS, NMOSD, and MOGAD: Part 1.
    Graf J; Mares J; Barnett M; Aktas O; Albrecht P; Zamvil SS; Hartung HP
    Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33406479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-β, glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab.
    Kemmerer CL; Pernpeintner V; Ruschil C; Abdelhak A; Scholl M; Ziemann U; Krumbholz M; Hemmer B; Kowarik MC
    PLoS One; 2020; 15(7):e0235449. PubMed ID: 32716916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unexpected exacerbations following initiation of disease-modifying drugs in neuromyelitis optica spectrum disorder: Which factor is responsible, anti-aquaporin 4 antibodies, B cells, Th1 cells, Th2 cells, Th17 cells, or others?
    Kira JI
    Mult Scler; 2017 Aug; 23(9):1300-1302. PubMed ID: 28391741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple sclerosis and neuromyelitis optica spectrum disorder testing and treatment availability in Latin America.
    Rojas JI; Gracia F; Patrucco L; Alonso R; Carnero Contentti E; Cristiano E
    Neurol Res; 2021 Dec; 43(12):1081-1086. PubMed ID: 34240685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individualized B cell-targeting therapy for neuromyelitis optica spectrum disorder.
    Kim SH; Hyun JW; Kim HJ
    Neurochem Int; 2019 Nov; 130():104347. PubMed ID: 30513364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. False positivity of anti aquaporin-4 antibodies in natalizumab-treated patients.
    Cohen M; De Sèze J; Marignier R; Lebrun C
    Mult Scler; 2016 Aug; 22(9):1231-4. PubMed ID: 26869528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiculopathy in neuromyelitis optica. How does anti-AQP4 Ab involve PNS?
    Kim S; Park J; Kwon BS; Park JW; Lee HJ; Choi JH; Nam K
    Mult Scler Relat Disord; 2017 Nov; 18():77-81. PubMed ID: 29141825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Condition-dependent generation of aquaporin-4 antibodies from circulating B cells in neuromyelitis optica.
    Wilson R; Makuch M; Kienzler AK; Varley J; Taylor J; Woodhall M; Palace J; Leite MI; Waters P; Irani SR
    Brain; 2018 Apr; 141(4):1063-1074. PubMed ID: 29447335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natalizumab promotes activation and pro-inflammatory differentiation of peripheral B cells in multiple sclerosis patients.
    Traub JW; Pellkofer HL; Grondey K; Seeger I; Rowold C; Brück W; Husseini L; Häusser-Kinzel S; Weber MS
    J Neuroinflammation; 2019 Nov; 16(1):228. PubMed ID: 31733652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct genetic and infectious profiles in Japanese neuromyelitis optica patients according to anti-aquaporin 4 antibody status.
    Yoshimura S; Isobe N; Matsushita T; Yonekawa T; Masaki K; Sato S; Kawano Y; Kira J;
    J Neurol Neurosurg Psychiatry; 2013 Jan; 84(1):29-34. PubMed ID: 23038741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications.
    Kaneko K; Sato DK; Nakashima I; Ogawa R; Akaishi T; Takai Y; Nishiyama S; Takahashi T; Misu T; Kuroda H; Tanaka S; Nomura K; Hashimoto Y; Callegaro D; Steinman L; Fujihara K; Aoki M
    J Neurol Neurosurg Psychiatry; 2018 Sep; 89(9):927-936. PubMed ID: 29875186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New biological agents in the treatment of multiple sclerosis.
    Buc M
    Bratisl Lek Listy; 2018; 119(4):191-197. PubMed ID: 29663814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers.
    Palace J; Leite MI; Nairne A; Vincent A
    Arch Neurol; 2010 Aug; 67(8):1016-7. PubMed ID: 20697055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of aquaporin-4 antibody assay in patients with neuromyelitis optica spectrum disorders.
    Kim SM; Waters P; Woodhall M; Kim JY; Kim JE; Yang JW; Kim JS; Sung JJ; Park KS; Lee KW
    Mult Scler; 2013 Jul; 19(8):1060-7. PubMed ID: 23329699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence of Müller Glial Dysfunction in Patients with Aquaporin-4 Immunoglobulin G-Positive Neuromyelitis Optica Spectrum Disorder.
    You Y; Zhu L; Zhang T; Shen T; Fontes A; Yiannikas C; Parratt J; Barton J; Schulz A; Gupta V; Barnett MH; Fraser CL; Gillies M; Graham SL; Klistorner A
    Ophthalmology; 2019 Jun; 126(6):801-810. PubMed ID: 30711604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production.
    Cotzomi E; Stathopoulos P; Lee CS; Ritchie AM; Soltys JN; Delmotte FR; Oe T; Sng J; Jiang R; Ma AK; Vander Heiden JA; Kleinstein SH; Levy M; Bennett JL; Meffre E; O'Connor KC
    Brain; 2019 Jun; 142(6):1598-1615. PubMed ID: 31056665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab-induced interstitial lung disease in a patient with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder.
    Ahn SH; Kim SM; Sung JJ
    Mult Scler Relat Disord; 2018 Feb; 20():192-193. PubMed ID: 29414297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease: current topics.
    Fujihara K; Cook LJ
    Curr Opin Neurol; 2020 Jun; 33(3):300-308. PubMed ID: 32374571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.